Identification of cap-dependent endonuclease inhibitors with broad-spectrum activity against bunyaviruses

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 119; no. 36; p. e2206104119
• Main Authors: Toba, Shinsuke, Sato, Akihiko, Kawai, Makoto, Taoda, Yoshiyuki, Unoh, Yuto, Kusakabe, Shinji, Nobori, Haruaki, Uehara, Shota, Uemura, Kentaro, Taniguchi, Keiichi, Kobayashi, Masanori, Noshi, Takeshi, Yoshida, Ryu, Naito, Akira, Shishido, Takao, Maruyama, Junki, Paessler, Slobodan, Carr, Michael J, Hall, William W, Yoshimatsu, Kumiko, Arikawa, Jiro, Matsuno, Keita, Sakoda, Yoshihiro, Sasaki, Michihito, Orba, Yasuko, Sawa, Hirofumi, Kida, Hiroshi
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 06.09.2022
• Subjects: Amino acids; Animals; Antiviral activity; Antiviral agents; Antiviral Agents - pharmacology; Biological Sciences; Carboxyl group; Drug Evaluation, Preclinical; Drug resistance; Drug Resistance, Viral - drug effects; Drug Resistance, Viral - genetics; Endonuclease; Endonucleases - antagonists & inhibitors; Gene sequencing; Genomes; Hemorrhage; Humans; Influenza; Mice; Orthobunyavirus - drug effects; Orthobunyavirus - genetics; Orthobunyavirus - metabolism; Public health; Ribavirin; Signs and symptoms; Structural analysis; Survival; Thrombocytopenia; Virus Replication - drug effects; Viruses; Whole genome sequencing; cap-dependent endonuclease; antiviral compounds; bunyavirus

Viral hemorrhagic fevers caused by members of the order comprise endemic and emerging human infections that are significant public health concerns. Despite the disease severity, there are few therapeutic options available, and therefore effective antiviral drugs are urgently needed to reduce disease...